Patrick Johnson, MD
Hematology & Oncology · Boston, MANPI 1164803573
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $82,967 of the $103,359 with a category attached, or 80.3%. 13 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 30.5% of the total. 2025 is the largest year on record at $53,942, more than ten times the $127 reported in 2021.
Across 91 payments — averaging $1135.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$32K
- Incyte Corporation$20K
- ADC Therapeutics America, Inc.$18K
- Seagen Inc.$11K
- AstraZeneca$11K
- Novartis$9K
- plus $4K from 7 others
Across 28 payments — averaging $172,070 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$4M
- Novartis$499K
- Incyte Corporation$296K
- Regeneron$24K
What the payments were for
- Consulting fees$82,96780%
- Speaking & faculty fees$8,4738%
- Travel & lodging$9,83410%
- Food & beverage$2,0862%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 14 | $31,507 |
| Incyte Corporation | 15 | $20,175 |
| ADC Therapeutics America, Inc. | 18 | $17,763 |
| Seagen Inc. | 9 | $10,959 |
| AstraZeneca | 6 | $10,587 |
| Novartis | 6 | $8,643 |
| Bristol Myers Squibb | 12 | $3,139 |
| Genentech USA, Inc. | 5 | $213 |
| Pfizer | 1 | $117 |
| GSK | 1 | $113 |
| Astrazeneca UK Limited | 1 | $60 |
| Gilead | 2 | $53 |
| Teleflex LLC | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$103,359 in reported general payments places this provider in the 85th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 23 | $338,683 |
| JakafiRuxolitinib Phosphate | 11 | $96,690 |
| CalquenceAcalabrutinib Maleate | 11 | $74,754 |
| FulphilaPegfilgrastim-Jmdb | 13 | $26,103 |
| Acyclovir | 34 | $540 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 28 | $221 |
| Prochlorperazine Maleate | 14 | $147 |
| Prednisone | 34 | $70 |
| Allopurinol | 12 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $20,175 | $96,69011 claims |
| AstraZenecaCalquence | $10,587 | $74,75411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 374 hematology & oncology providers in Massachusetts.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.